Intra-Cellular Therapies Growth, Revenue, Number of Employees and Funding


Total Funding:$20.9M
Lead Investor(s):J.P. Morgan Securities LLC, Leerink Partners LLC

Revenue & Financials

  • Intra-Cellular Therapies's revenue is currently $9.2M per year.
  • Intra-Cellular Therapies received $150.0M in venture funding in September 2017.
  • Intra-Cellular Therapies's revenue per employee is $162211
  • Intra-Cellular Therapies's total funding is $20.9M.

Employee Data

  • Intra-Cellular Therapies has 57 Employees.
  • Intra-Cellular Therapies grew their employee count by 24% last year.
  • Intra-Cellular Therapies currently has 1 job openings.

What Is Intra-Cellular Therapies?

Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications. Use link below for a listing of Job Opportunities:



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Symbio Research
Innovation Asso...
Insight Strateg...
LI Script LLC
Medical Knowled...
CHDI Foundation
Intra-Cellular ...
Rochem Internat...

Intra-Cellular Therapies News

20-Mar-19 - Intra-cellular Therapies Inc (NASDAQ:ITCI) Institutional Investors

Intra-cellular Therapies Inc (NASDAQ:ITCI) institutional sentiment decreased to 0.93 in Q4 2018. Its down -0.01, from 0.94 in 2018Q3. The ratio

27-Feb-19 - Intra-Cellular Therapies up 2% on Q4 results

Intra-Cellular Therapies (ITCI) Q4 results: Revenues: $0; R&D Expense: $33.6M (+24.9%); SG&A: $9M (+55.2%); Net Loss: ($40.7M) (-34.8%);

13-Mar-19 - Don't Miss The True Potential: Intra-Cellular Therapies, Inc. (ITCI

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) popped in on a low volume green day. Volume on 12-Mar-19 came in at 246792 contracts.

Intra-Cellular Therapies Funding

DateAmountRoundLead InvestorsReference
2014-02-03$100.2MUndisclosedLeerink Partners LLCArticle
2014-02-06$115.3MUndisclosedLeerink Partners LLCArticle
2015-03-09$106.5MUndisclosedLeerink Partners LLCArticle
2015-03-13$121.4MUndisclosedLeerink Partners LLC,Article
2017-09-29$150.0MUndisclosedJ.P. Morgan Securities LLCArticle

Intra-Cellular Therapies Executive Hires

2014-03-11Juan SanchezVP Corporate Communications/Investor RelationsArticle
2018-08-21Suresh DurgamSVP Late Stage Clinical Development & Medical Affairs.Article
2018-09-26Michael OlchaskeySVP/Head of Regulatory AffairsArticle